Zinc binding groups for histone deacetylase inhibitors

被引:183
作者
Zhang, Lei [1 ]
Zhang, Jian [1 ]
Jiang, Qixiao [2 ]
Zhang, Li [2 ]
Song, Weiguo [1 ]
机构
[1] Weifang Med Univ, Sch Pharm, Dept Med Chem, Weifang, Shandong, Peoples R China
[2] Qingdao Univ, Sch Pharm, Qingdao, Shandong, Peoples R China
关键词
Histone deacetylase inhibitor; zinc binding group; anti-tumour; selectivity; drug design; PHASE-I; CARDIAC-HYPERTROPHY; VALPROIC ACID; ORAL CI-994; POTENT; COMBINATION; IDENTIFICATION; MGCD0103; CANCER; ST7612AA1;
D O I
10.1080/14756366.2017.1417274
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Zinc binding groups (ZBGs) play a crucial role in targeting histone deacetylase inhibitors (HDACIs) to the active site of histone deacetylases (HDACs), thus determining the potency of HDACIs. Due to the high affinity to the zinc ion, hydroxamic acid is the most commonly used ZBG in the structure of HDACs. An alternative ZBG is benzamide group, which features excellent inhibitory selectivity for class I HDACs. Various ZBGs have been designed and tested to improve the activity and selectivity of HDACIs, and to overcome the pharmacokinetic limitations of current HDACIs. Herein, different kinds of ZBGs are reviewed and their features have been discussed for further design of HDACIs.
引用
收藏
页码:714 / 721
页数:8
相关论文
共 69 条
[41]   Panobinostat for the treatment of multiple myeloma [J].
Neri, Paola ;
Bahlis, Nizar J. ;
Lonial, Sagar .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (05) :733-747
[42]   Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases [J].
Nishino, N ;
Jose, B ;
Okamura, S ;
Ebisusaki, S ;
Kato, YT ;
Sumida, Y ;
Yoshida, M .
ORGANIC LETTERS, 2003, 5 (26) :5079-5082
[43]   Tropolones As Lead-Like Natural Products: The Development of Potent and Selective Histone Deacetylase Inhibitors [J].
Ononye, Sophia N. ;
VanHeyst, Michael D. ;
Oblak, E. Zachary ;
Zhou, Wangda ;
Ammar, Mohamed ;
Anderson, Amy C. ;
Wright, Dennis L. .
ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (08) :757-761
[44]   A Structure-Based Virtual Screening Approach toward the Discovery of Histone Deacetylase Inhibitors: Identification of Promising Zinc-Chelating Groups [J].
Park, Hwangseo ;
Kim, Sukyoung ;
Kim, Yong Eun ;
Lima, Soo-Jeong .
CHEMMEDCHEM, 2010, 5 (04) :591-597
[45]   3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition [J].
Patil, Vishal ;
Sodji, Quaovi H. ;
Kornacki, James R. ;
Mrksich, Milan ;
Oyelere, Adegboyega K. .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (09) :3492-3506
[46]   Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors [J].
Pauer, LR ;
Olivares, J ;
Cunningham, C ;
Williams, A ;
Grove, W ;
Kraker, G ;
Olson, S ;
Nemunaitis, J .
CANCER INVESTIGATION, 2004, 22 (06) :886-896
[47]   Chronic oral administration of CI-994: A phase 1 study [J].
Prakash, S ;
Foster, BJ ;
Meyer, M ;
Wozniak, A ;
Heilbrun, LK ;
Flaherty, L ;
Zalupski, M ;
Radulovic, L ;
Valdivieso, M ;
LoRusso, PM .
INVESTIGATIONAL NEW DRUGS, 2001, 19 (01) :1-11
[48]   A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases [J].
Richon, VM ;
Emiliani, S ;
Verdin, E ;
Webb, Y ;
Breslow, R ;
Rifkind, RA ;
Marks, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (06) :3003-3007
[49]   Inside HDACs with more selective HDAC inhibitors [J].
Roche, Joelle ;
Bertrand, Philippe .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 121 :451-483
[50]   Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection [J].
Roger, Thierry ;
Lugrin, Jerome ;
Le Roy, Didier ;
Goy, Genevieve ;
Mombelli, Matteo ;
Koessler, Thibaud ;
Ding, Xavier C. ;
Chanson, Anne-Laure ;
Reymond, Marlies Knaup ;
Miconnet, Isabelle ;
Schrenzel, Jacques ;
Francois, Patrice ;
Calandra, Thierry .
BLOOD, 2011, 117 (04) :1205-1217